Clinical Scorecard: Analysis of Five Cases of POU2F3-Positive Small Cell Neuroendocrine Carcinoma in the Urinary Tract: A Clinicopathological Study

At a Glance

Key Highlights

• Five cases of POU2F3-positive SmCC were analyzed.
• Common symptoms included gross hematuria and lower abdominal pain.
• Histological features included small round blue cells with high nuclear-to-cytoplasmic ratio.
• All cases showed diffuse POU2F3 expression and loss of conventional neuroendocrine markers.
• Distant metastases occurred in three patients during follow-up.

Guideline-Based Recommendations

Diagnosis

• Diagnosis established according to the 2022 WHO Classification of Urinary and Male Genital Tumours.

Management

• Transurethral resection of bladder tumor was performed in two cases.

Monitoring & Follow-up

• Follow-up indicated distant metastases in three patients.

Risks

• Associated with poor prognosis due to rapid progression and advanced stage at diagnosis.

Patient & Prescribing Data

Five patients aged 62 to 70 years, with no prior history of malignancy.

Treatment involved surgical resection; further management details not specified.

Clinical Best Practices

• Utilize POU2F3 expression as a diagnostic marker for urinary tract SmCC.
• Consider molecular heterogeneity in SmCC when interpreting neuroendocrine marker expression.

Related Resources & Content

• 2022 WHO Classification of Urinary and Male Genital Tumours